Can-Fite Biopharma Ltd ADR (CANF) Stock Price, Quote & News

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 924 1114

Fax: 972 3 924 9378

Website: www.canfite.com

Address:

26 Ben Gurion Street, Ramat Gan, Israel

ValuePrince Sep. 13 at 11:59 AM

$CANF 🐳

0 · Reply

Davefuhr Sep. 9 at 1:37 PM

$CANF This morning the borrow rate is 161.5%. The highest that I have seen yet. Are the shorts really true believers in their thesis or is there something else hoing on? (manipulation?)

0 · Reply

Stock_Catcher Sep. 8 at 12:20 PM

$CANF Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

0 · Reply

Donniechen12345 Sep. 4 at 6:33 PM

$CANF @MSG8898 explode for another scam reverse split of trash offering for the 20th time in the last 5 years after a PR comes out , go look up their scam offering and reverse split history lmao !!!!!!!

0 · Reply

stevieulder Sep. 4 at 6:21 PM

$CANF new atl

0 · Reply

stevieulder Sep. 4 at 1:36 PM

$CANF A perfect scam stock

0 · Reply

Hkarawi Sep. 4 at 10:54 AM

$CANF this will go up once offering is closed

0 · Reply

Mr_SessionSpike Sep. 3 at 8:20 PM

$CANF stay away from this stock.

0 · Reply

Donniechen12345 Sep. 3 at 7:10 PM

$CANF can’t believe this fraud scam stock is still trading haha ….. 20th scam offering or reverse split in the last 10 years Lmao

0 · Reply

MSG8898 Sep. 3 at 4:42 PM

$CANF with interim results on liver cancer this is poised to explode!

0 · Reply

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Tue, 08 Sep 2026 08:20:00 -0400 - 5 days ago

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

2026-09-02T14:28:29.000Z - 11 days ago

Can-Fite Enters Warrant Exercise Deal For $4 Mln, Shares To Be Issued At Discount; Stock Plunges

2026-09-02T13:30:36.000Z - 11 days ago

CANF Looks 45.6% Undervalued on GF Valueâ¢ Despite Challenging Fundamentals

Wed, 02 Sep 2026 09:02:00 -0400 - 11 days ago

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

2026-09-02T11:41:02.000Z - 11 days ago

Can-Fite reports longer-than-anticipated survival observed in Namodenoson study

Wed, 02 Sep 2026 07:00:00 -0400 - 11 days ago

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

2026-08-28T20:20:15.000Z - 16 days ago

Can-Fite BioPharma files $100M mixed securities shelf

Aug 28, 2026, 8:00 AM EDT - 16 days ago

Can-Fite BioPharma Registration statement: Registration filing

2026-08-17T15:45:44.000Z - 27 days ago

Can-Fite Releases Positive Data For Namodenoson In Treating Pancreatic Cancer

Mon, 17 Aug 2026 07:00:00 -0400 - 27 days ago

Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

2026-08-12T14:46:12.000Z - 4 weeks ago

Can-Fite Advances Phase III Programs; Namodenoson Retains FDA Fast Track Status

Wed, 12 Aug 2026 07:00:00 -0400 - 4 weeks ago

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

2026-08-03T11:55:23.000Z - 5 weeks ago

Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu

Mon, 03 Aug 2026 07:00:00 -0400 - 5 weeks ago

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Mon, 20 Jul 2026 07:00:00 -0400 - 7 weeks ago

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

2026-07-14T12:30:17.000Z - 2 months ago

Can-Fite BioPharma (CANF) Secures Patent for Cancer Treatment

2026-07-14T11:15:18.000Z - 2 months ago

Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson

Tue, 14 Jul 2026 07:00:00 -0400 - 2 months ago

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer

2026-07-06T12:27:37.000Z - 2 months ago

Can-Fite BioPharma (CANF) Completes Patient Enrollment for Psoriasis Study

2026-07-06T11:15:42.000Z - 2 months ago

Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial

Mon, 06 Jul 2026 07:00:00 -0400 - 2 months ago

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

2026-07-02T13:07:25.000Z - 2 months ago

CANF Reiterated by HC Wainwright & Co. -- Price Target Raised to $8

2026-07-02T10:00:15.000Z - 2 months ago

Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright

2026-07-01T12:40:34.000Z - 2 months ago

Can-Fite BioPharma (CANF) Reports Positive Results in Namodenoson Study

2026-07-01T11:57:57.000Z - 2 months ago

Can-Fite's Namodenoson Shows Survival Benefits In Pancreatic Cancer; Stock Jumps Pre-Market

2026-07-01T11:05:11.000Z - 2 months ago

Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint

Wed, 01 Jul 2026 07:00:00 -0400 - 2 months ago

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

2026-06-26T12:31:28.000Z - 2 months ago

Can-Fite BioPharma (CANF) Secures Key Patent for Fat Loss Treatment

2026-06-26T11:05:19.000Z - 2 months ago

Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists

Fri, 26 Jun 2026 07:00:00 -0400 - 2 months ago

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

Mon, 22 Jun 2026 07:00:00 -0400 - 2 months ago

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

Wed, 17 Jun 2026 07:00:00 -0400 - 2 months ago

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026

Tue, 02 Jun 2026 07:00:00 -0400 - 3 months ago

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism

Mon, 18 May 2026 07:00:00 -0400 - 3 months ago

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

2026-05-13T13:49:05.000Z - 4 months ago

Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital

Wed, 13 May 2026 07:00:00 -0400 - 4 months ago

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

2026-05-12T10:49:37.000Z - 4 months ago

Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright

Thu, 30 Apr 2026 08:31:00 -0400 - 4 months ago

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Can-Fite BioPharma Registration statement: Registration filing

2026-03-31T10:16:55.000Z - 5 months ago

Can-Fite BioPharma files to sell 3.29M ordinary shares for holders

2026-03-30T22:03:00.000Z - 5 months ago

Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs

2026-03-30T11:37:18.000Z - 5 months ago

Can-Fite BioPharma completes enrollment in Piclidenoson study

Mon, 30 Mar 2026 07:20:00 -0400 - 5 months ago

Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Mar 26, 2026, 9:30 AM EDT - 5 months ago

Can-Fite BioPharma Annual report: Q4 2025

Mar 26, 2026, 9:30 AM EDT - 5 months ago

Can-Fite BioPharma Quarterly report: Q4 2025

Thu, 26 Mar 2026 09:27:00 -0400 - 5 months ago

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

2026-03-17T13:28:03.000Z - 6 months ago

Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment

2026-03-17T11:50:14.000Z - 6 months ago

Can-Fite BioPharma announces Israeli patent allowance for namodenoson

Tue, 17 Mar 2026 07:47:00 -0400 - 6 months ago

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

2026-03-04T16:50:16.000Z - 6 months ago

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

Wed, 04 Mar 2026 10:07:28 -0500 - 6 months ago

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

2026-03-04T12:34:33.000Z - 6 months ago

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

2026-03-04T12:09:03.000Z - 6 months ago

Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study

Mar 4, 2026, 7:00 AM EST - 6 months ago

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

2026-02-17T12:15:35.000Z - 6 months ago

Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson

2026-02-09T12:15:27.000Z - 7 months ago

Can-Fite BioPharma receives Canadian patent allowance for namodenoson

2026-02-05T12:17:59.000Z - 7 months ago

Can-Fite announces patient with liver cirrhosis treated with Namodenoson

2026-01-20T12:10:21.000Z - 7 months ago

Can-Fite completes patient enrollment in Phase 2a study of Namodenoson

2025-12-24T15:50:08.000Z - 8 months ago

Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital

Dec 23, 2025, 4:46 PM EST - 8 months ago

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

Dec 16, 2025, 9:19 AM EST - 9 months ago

Can-Fite Provides Update on Clinical and Financial Status

Nov 20, 2025, 7:00 AM EST - 9 months ago

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

Aug 28, 2025, 8:47 AM EDT - 1 year ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Aug 27, 2025, 6:00 PM EDT - 1 year ago

Can-Fite BioPharma Quarterly report: Q2 2025

Jul 30, 2025, 7:04 AM EDT - 1 year ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Jul 28, 2025, 12:24 PM EDT - 1 year ago

Can-Fite Announces Up To $15.0 Million Public Offering

Jul 28, 2025, 7:00 AM EDT - 1 year ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Registration statement: Registration Filing

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Registration statement: Registration Filing

Apr 17, 2025, 8:55 AM EDT - 1 year ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Apr 14, 2025, 2:28 PM EDT - 1 year ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Annual report: Q4 2024

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Quarterly report: Q4 2024

Mar 20, 2025, 9:45 AM EDT - 1 year ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Mar 19, 2025, 9:00 AM EDT - 1 year ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mar 3, 2025, 6:00 AM EST - 1 year ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Feb 10, 2025, 7:10 AM EST - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Feb 5, 2025, 7:00 AM EST - 1 year ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Dec 30, 2024, 7:00 AM EST - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Nov 23, 2024, 7:01 PM EST - 1 year ago

Can-Fite BioPharma Transcript: C-level Sitdown

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SXTP

Nov 11, 2024, 7:00 AM EST - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Nov 4, 2024, 7:08 AM EST - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Oct 29, 2024, 4:15 PM EDT - 1 year ago

Can-Fite BioPharma Transcript: Investor Update

Oct 18, 2024, 9:06 AM EDT - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Oct 9, 2024, 7:00 AM EDT - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Aug 30, 2024, 8:00 AM EDT - 2 years ago

Can-Fite BioPharma Registration statement: Registration Filing

Aug 29, 2024, 8:15 AM EDT - 2 years ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 29, 2024, 7:00 AM EDT - 2 years ago

Can-Fite BioPharma Earnings release: Q2 2024

Aug 10, 2024, 7:00 PM EDT - 2 years ago

Can-Fite BioPharma Transcript: C-level Sitdown

Aug 9, 2024, 9:00 AM EDT - 2 years ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Aug 8, 2024, 7:01 PM EDT - 2 years ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Aug 8, 2024, 4:15 PM EDT - 2 years ago

Can-Fite BioPharma Transcript: Investor Update

Jul 29, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Provides Namodenoson Patent Update

Jul 17, 2024, 7:00 AM EDT - 2 years ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 11, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jun 28, 2024, 7:00 AM EDT - 2 years ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

ValuePrince Sep. 13 at 11:59 AM

$CANF 🐳

0 · Reply

Davefuhr Sep. 9 at 1:37 PM

$CANF This morning the borrow rate is 161.5%. The highest that I have seen yet. Are the shorts really true believers in their thesis or is there something else hoing on? (manipulation?)

0 · Reply

Stock_Catcher Sep. 8 at 12:20 PM

$CANF Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

0 · Reply

Donniechen12345 Sep. 4 at 6:33 PM

0 · Reply

stevieulder Sep. 4 at 6:21 PM

$CANF new atl

0 · Reply

stevieulder Sep. 4 at 1:36 PM

$CANF A perfect scam stock

0 · Reply

Hkarawi Sep. 4 at 10:54 AM

$CANF this will go up once offering is closed

0 · Reply

Mr_SessionSpike Sep. 3 at 8:20 PM

$CANF stay away from this stock.

0 · Reply

Donniechen12345 Sep. 3 at 7:10 PM

$CANF can’t believe this fraud scam stock is still trading haha ….. 20th scam offering or reverse split in the last 10 years Lmao

0 · Reply

MSG8898 Sep. 3 at 4:42 PM

$CANF with interim results on liver cancer this is poised to explode!

0 · Reply

Mr_SessionSpike Sep. 3 at 2:53 PM

$CANF get out before you loss more.

0 · Reply

slickinvest Sep. 3 at 11:48 AM

$CANF get the fuck away from this Israeli company. They steal enough from our tax money to fund their fraud, scam and terrorism.

2 · Reply

translucide Sep. 3 at 11:47 AM

$CANF Next financing round in 6 months for another 4m$ over 7m$ valuation...75 cents by Feb 2027... They will need a stock split much sooner than before ... They did an RS each 4 years or so before, now it's each year ? Seems like they need a lot more cash these days.

0 · Reply

Rampageusa Sep. 3 at 11:41 AM

$CANF Bingo called it out a scam co to buy under 2 here she goes….sec should block such scam cos..

0 · Reply

MadMaverick Sep. 3 at 1:01 AM

⚡WATCHLIST RECAP ⚡ $VIVK $JLHL $PPBT $CANF

0 · Reply

StuckAtTheTop Sep. 2 at 11:40 PM

$CANF this POS reminded me why you don’t trade premarket if you added this there was no way In hell you could have gotten out without a fat loss, thankfully was only starter at 4.01 I lucky got out 3.70 before the complete shit show

1 · Reply

lgb2 Sep. 2 at 7:14 PM

$CANF I made 100% profit

0 · Reply

Market Cap	1.53M
Revenue (ttm)	410,000.00
Net Income (ttm)	-9.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,397.56%
Debt to Equity Ratio	0.00

Volume	154,900
Avg Vol	530,832
Day's Range	N/A - N/A
Shares Out	655,000.00
Stochastic %K	13%
Beta	1.12
Analysts	Strong Sell
Price Target	$6.50